The Healthcare Technology Report is pleased to announce The Top 50 Healthcare Technology CEOs of 2024. This year’s list features individuals whose leadership has been a driving force behind some of the most significant advancements in healthcare. These CEOs have inspired their teams to push boundaries, fostering cultures of innovation that have led to transformative breakthroughs in medical devices, digital health, software, biotechnology, and beyond.
Their ability to lead through change, inspire their organizations, and innovate in the face of healthcare’s most pressing challenges has positioned their companies as leaders in the field, driving progress to improve patient care and global health.
Among this year’s awardees, Steve Chapman, CEO of Natera, is recognized for his leadership in genetic testing, overseeing the launch of 20 transformative products in oncology, women’s health, and organ health, including the Signatera oncology test and the Prospera transplant assessment test. Thomas Sandgaard, CEO of Zynex Medical, is celebrated for his work in medical technology, leading the company’s growth in pain management and rehabilitation through solutions like wearable electrotherapy devices that help improve patient outcomes. Randall Lipps, CEO of Omnicell, stands out for his expertise in pharmacy care, revolutionizing medication management with solutions that enhance operational efficiency, support compliance, and reduce costs across health systems globally.
This year’s awardees were selected through a methodical nomination process and careful consideration of each candidate’s career track record and industry contributions. Please join us in celebrating The Top 50 Healthcare Technology CEOs of 2024.
1. Steve Chapman
Company: Natera
Title: Chief Executive Officer
Steve Chapman is the Chief Executive Officer of Natera, a global leader in cell-free DNA and genetic testing in oncology, women’s health, and organ health. He also serves on the company’s board of directors.
Chapman is a leading authority on the commercialization of genetic testing. Under his leadership, Natera has launched 20 products that have transformed patient care, including two of the fastest growing genetic tests of all time. The company’s suite of products includes the Signatera oncology test for molecular residual disease, the Prospera transplant assessment test, the Renasight kidney gene panel which screens for genetic causes of chronic kidney disease, and the highly differentiated Panorama test serving patients in the non-invasive prenatal testing market.
Before his appointment as CEO in 2019, Chapman held a number of other leadership positions at Natera, including Chief Operating Officer. Earlier in his career, he worked at Genzyme Genetics. He began his career as a researcher in the department of human genetics at the University of California, Los Angeles, where he designed arrays identifying SNPs associated with multiple sclerosis.
Chapman is an author on multiple scientific papers and holds a bachelor’s degree in microbiology, immunology, and molecular genetics from UCLA.
2. Thomas Sandgaard
Company: Zynex Medical
Title: Founder, Chairman and Chief Executive Officer
Thomas Sandgaard has been the Chairman of the Board, President, and Chief Executive Officer of Zynex since founding the company in 1996. He has previously held management positions with companies such as ITT, Siemens, GN Danavox, Dataco, and Philips. Most of his work has been in the areas of international sales and distribution, technology transfers, mergers and marketing management in the semiconductor, telecommunications, data communications, and medical equipment industries.
Mr. Sandgaard is also the Founder and CEO of Sandgaard Capital, a private equity investment group and family office. He is also the Founder and President of the Sandgaard Foundation, seeking to address the United States tragic opioid and fentanyl crisis by helping to fund initiatives that save lives from overdose, help people escape the cycle of relapse, and support victims and their families.
Mr. Sandgaard holds a degree in electronics engineering from Denmark’s Odense University of Engineering and an MBA from Copenhagen Business School.
3. Randall Lipps
Company: Omnicell
Title: Chief Executive Officer and Founder
Randall Lipps is the Chairman, President, Chief Executive Officer, and Founder of Omnicell, a global leader in transforming the pharmacy care delivery model. Inspired by inefficiencies he observed during his daughter's hospitalization, Mr. Lipps founded Omnicell in 1992, leveraging his background in airline operations to improve medication management and patient care.
Under his leadership, Omnicell has grown from a single product to a comprehensive portfolio of solutions that are helping health systems worldwide to uncover cost savings, improve labor efficiency, establish new revenue streams, enhance supply chain control, support compliance, and move closer to the industry-defined vision of the autonomous pharmacy.
A member of the Board of Trustees of the American Nurses Foundation, Mr. Lipps champions community impact through Omnicell Cares and personal philanthropy focused on poverty, education, and healthcare. He holds dual bachelor’s degrees in economics and business administration from Southern Methodist University.
4. Charles Brown
Company: LifeLabs
Title: President and Chief Executive Officer
Charles Brown is the President and Chief Executive Officer of LifeLabs Medical Laboratory, Canada’s leading provider of laboratory diagnostic information and digital health connectivity systems, enabling patients and healthcare practitioners to diagnose, treat, monitor, and prevent disease. Since joining LifeLabs in 2018, Charles has worked to evolve LifeLabs into a commercially driven organization that brings customer-centred value to market.
By showcasing the possibility of delivering value-based outcomes, Charles empowers his employees to make a difference and facilitate innovative change. During COVID-19, Charles’ leadership empowered the team to quickly pivot and adapt to respond to the pandemic by providing essential COVID-19 testing, while maintaining full operation of lab testing and diagnostic work.
Previously, Brown was the President of The Source and Executive Vice President of Strategic Initiatives at Bell. Brown also served as the Chair of Kids Help Phone and for the University of Toronto-Scarborough’s Campaign Cabinet. He was also a past member and supporter of the United Way of Toronto and York Region’s Campaign Cabinet.
Brown holds a bachelor’s degree from the University of Toronto and an MBA from the Ivey School of Business at Western University. He was previously recognized as a Top 25 Biotechnology CEO by the Healthcare Technology Report in both 2021 and 2022.
5. Devdatt Kurdikar
Company: embecta
Title: President and Chief Executive Officer
Devdatt (Dev) Kurdikar serves as the President and Chief Executive Officer of embecta, a global diabetes care company with a 100-year legacy in insulin delivery. Kurdikar led the business through its successful spinoff from BD in 2022 to become an independent, publicly-traded company that serves 30 million people in more than 100 countries.
Since the spinoff, embecta has strengthened its core business, completed major stand-up programs and invested in growth, exceeding expectations across key financial metrics while navigating macroeconomic issues that included historic inflation, a rapidly rising interest rate environment, geopolitical conflicts, and supply chain and labor issues.
Prior to leading embecta, Dev served as President and CEO of Cardiac Science Corporation, a leader in the manufacturing and marketing of automated external defibrillators. He also served as Vice President and General Manager of Men’s Health at Boston Scientific and American Medical Systems.
Prior to that, he served as Vice President of Marketing at Baxter International, where over the course of 11 years he held leadership roles of increasing responsibility in finance, strategy and integration, R&D planning and operations. He began his career as a senior research engineer at The Monsanto Company.
Dev is currently a member of the Board of Directors of Zimmer Biomet Holdings, AdvaMed, and LMG Holdings. He holds a bachelor’s degree in chemical engineering from the University of Bombay, a master’s degree in chemical engineering from Washington State University, a PhD in chemical engineering from Purdue University, and an MBA from Washington University.
6. Matthew Trerotola
Company: Enovis Corporation
Title: Chief Executive Officer
Matt Trerotola is the Chief Executive Officer of Enovis, a position he has held since 2015 (when the company was known as Colfax), and Chairman of the Board of Directors since 2023. Under his leadership, the company has undergone a transformative journey, driven by his focus on improving patient outcomes and advancing innovation in the healthcare sector.
Under his leadership, the company solidified its corporate capabilities, developed a powerful business system called Enovis Growth Excellence, and continues to pursue a disciplined M&A approach. This dynamic combination has powered Enovis’ global growth and expansion, with the addition of 20 new acquisitions since 2019.
In 2022, Mr. Trerotola led the company’s rebrand, spearheading double-digit growth across many business units and dozens of product launches, gaining recognition for both the ARVIS augmented reality system and MotionIQ recovery app. Enovis is a leader in the medtech industry, with more than 1,000 total medical devices, 1,200 patents held, and over 7,000 employees globally.
Prior to joining Enovis, Mr. Trerotola was an Executive Vice President at DuPont, where he was responsible for $6.3 billion of revenue in safety and protection and electronic materials. He also held several leadership roles at Danaher, including serving as Vice President and Group Executive for the $2.5 billion life sciences platform. During his tenure in these roles, Mr. Trerotola strengthened talent, greatly accelerated organic growth, improved profitability, and made strategic acquisitions. He also serves on the board of directors of the Boys and Girls Clubs of Delaware.
7. Kyoko (Kay) Deguchi
Company: PHC Holdings
Title: President, Representative Director, and Chief Executive Officer
Kyoko (Kay) Deguchi is the Chief Executive Officer of PHC Holdings Corporation, a global collection of healthcare businesses referred to collectively as PHC Group. Together, PHC Group companies are focused on precision technology that powers the future of healthcare. PHC Group companies and brands include Ascensia (diabetes management), Epredia (cancer diagnostic solutions), PHCbi (cell preservation and growth), PHC IVD (in vitro diagnostics), Wemex (healthcare IT), LSI Medience (clinical testing), and Mediford (drug development).
Kay joined PHC Group as an independent external board director in 2021, bringing over two decades of experience as a business leader, including in the healthcare industry. She became CEO in April 2024, and in her first six months launched an updated vision and value creation plan outlining PHC Group’s new global strategy to focus future growth on diagnostics and life sciences. During this time, Kay engaged with more than 500 employees through roundtables across PHC Group’s subsidiaries, discussing how the company can enhance its collective impact on health through precision technology.
As PHC Group’s first female CEO, Kay is a modern leader for an increasingly diverse company and industry. She prioritizes inclusion and is a vocal proponent of the concept of “One PHC,” a company mindset that seeks to create synergies across divisions and disciplines to create greater value for researchers, healthcare providers, and the patients they serve.
8. Kevin Adams
Company: UST HealthProof
Title: Chief Executive Officer and Co-Founder
Kevin Adams is the Co-Founder and Chief Executive Officer of UST HealthProof, where he leads the transformation of healthcare operations, processes, and products. Under his leadership, UST HealthProof has grown into a global organization with nearly 5,000 employees. Kevin's strategic vision and commitment to innovation, agility, and customer-centricity have been instrumental in identifying and capitalizing on business opportunities. Alongside a team of seasoned industry experts, Kevin delivers platform-based solutions, business advisory services, and system implementations that drive significant advancements in healthcare.
Kevin’s expertise in building successful businesses is evident in his ability to inspire and lead diverse teams, foster innovation, and maintain a strong focus on customer needs. As a pioneer in implementing BPaaS in healthcare, his forward-thinking approach has led to the adoption of solutions that empower health plans to overcome complex operational challenges and compete in an evolving market. He has led UST HealthProof through periods of transformation with a focus on adaptability and resilience.
Before founding UST HealthProof in 2016, Kevin served as the Chief Technology Officer for UST Global Healthcare, where he led IT strategy and business direction. He also held the position of Chief Technology Officer at Edifecs, where he helped the company navigate and leverage ongoing technological changes. Kevin’s extensive experience working with and for health plans and his ability to lead a global organization with integrity and vision make him a standout leader in the healthcare technology industry.
9. Jason Brown
Company: MRO
Title: Chief Executive Officer
Jason Brown is the Chief Executive Officer of MRO, a company specializing in the exchange of clinical data within the healthcare ecosystem. MRO works on behalf of providers, payers, and users of clinical data to streamline and manage the exchange process through advanced solutions and technology. With a 22-year legacy, MRO combines a technology-driven approach with a client-first service foundation, providing healthcare organizations with scalable, enterprise-wide clinical data solutions.
Before joining MRO, Jason was CEO of Discovery Health Partners, a provider of payment and revenue integrity technology solutions to health plans and was acquired by MultiPlan in March 2021. Prior to that, Jason helped build several healthcare technology companies, including Evolent Health, Valence Health and MedAssets. Jason’s early career experience includes time working at The Boston Consulting Group, The Home Depot, Goldman Sachs, and Vista Equity Partners. He is a graduate of Morehouse College and holds a MBA from Harvard Business School.
10. Terrie Curran
Company: Phathom Pharmaceuticals
Title: President and Chief Executive Officer
Terrie Curran is the President and Chief Executive Officer of Phathom Pharmaceuticals, a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal diseases since 2019. Phathom’s mission is to transform the treatment landscape and improve the lives of patients suffering from acid-related GI disorders.
Under Curran’s leadership, the company has established a strong commercial organization and introduced the first new class of treatment for Gastroesophageal Reflux Disease (GERD) in over 30 years, marking a significant advancement in the field of acid-related GI disorders.
Curran is the former President, Global Inflammation and Immunology (I&I) Franchise and member of the Executive Committee at Celgene Corporation and has more than 20 years of experience in the biopharmaceutical industry. Curran joined Celgene in 2013 as the U.S. Commercial Head of the I&I Franchise and built the capabilities and recruited the teams that executed the successful launch of OTEZLA.
Prior to joining Celgene, she served as Senior Vice President and General Manager, Global Women’s Health at Merck & Co. She currently serves on the Board of Arcutis Biotherapeutics, and previously served on the Board of Myovant Sciences and H. Lundbeck A/S. Curran holds graduate and bachelor’s degrees from the University of Technology Sydney.
11. BJ Schaknowski
Company: Symplr
Title: Chief Executive Officer
BJ Schaknowski is the Chief Executive Officer of Symplr, bringing over 20 years of experience in leadership roles across various functions within the software industry. Before joining Symplr, BJ served as the Chief Sales & Marketing Officer at Vertafore, a leading provider of insurance technology. He also spent four years at LexisNexis Software Solutions, where he advanced to the role of SVP of Marketing, Sales & Services. Earlier in his career, BJ held senior leadership positions at CA Technologies, Intuit, and Sage Software.
BJ is committed to creating balanced value for employees, customers, and shareholders within the Symplr community. He has a strong focus on philanthropy and was recently appointed to the Susan G. Komen Board of Directors, joining a select group of executives from various industries who help govern and advise the organization. BJ is also a Fellow of the American College of Health Data Management.
BJ holds a bachelor’s degree in communications from the State University of New York at Geneseo and an MBA at the University of Georgia Terry College of Business. Schaknowski also served in the United States Marine Corps infantry as an enlisted reservist for eight years.
12. Scott Turicchi
Company: Consensus Cloud Solutions
Title: Chief Executive Officer
Scott Turicchi is the Chief Executive Officer of Consensus Cloud Solutions, a provider of digital cloud fax technology and interoperability solutions. With over 25 years of experience in the industry, the company has expanded its services to include artificial intelligence and secure data exchange, aimed at automating workflows and improving operational efficiencies. Consensus also upholds industry compliance standards, serving a range of heavily regulated industries, including healthcare, the public sector, financial services, insurance, real estate, and manufacturing.
Turicchi joined J2 Global in 2000 and eventually led the spinoff of Consensus Cloud Solutions in 2021, where he currently oversees a staff of nearly 525 employees. At Consensus, Scott leads efforts to enhance how organizations exchange information securely through cloud-based solutions, including digital communication, secure messaging, patient query, electronic signature capabilities, and tools for data transformation and artificial intelligence.
During his more than two-decade tenure with J2 Global, Scott was elevated from Executive Vice President of Corporate Development to CFO and ultimately was named President and CFO in 2008, responsible for all finance, merger and acquisitions activity and public company matters. Under his leadership, J2 Global successfully acquired and integrated approximately 200 businesses across its digital media and cloud services segments, leading to revenue growth that reached $1.5 billion in FY 2021.
13. Chris Mansi
Company: Viz.ai
Title: Chief Executive Officer and Co-Founder
Chris Mansi, MD is Chief Executive Officer and Co-Founder of Viz.ai, a leader in AI-powered disease detection and care coordination. Viz.ai’s mission is to improve access to life saving treatments for more than 230 million people that it covers. Today, the Viz.ai One Platform has 30 care pathways, is adopted in more than 1,700 hospitals, and collaborates with 10 of the leading, global pharmaceutical and medical device companies.
Dr. Mansi co-founded Viz.ai out of Stanford in 2016 with a mission of using artificial intelligence to increase access to life-saving treatments. Under his leadership, Viz.ai has achieved major AI industry milestones, including two de novo approvals by the FDA for AI computer aided triage in 2018 and cardiovascular machine learning-based notification software in 2023. Viz.ai was also the first AI company to be granted CMS reimbursement via the New Technology Add-on Payment (NTAP) for AI in 2020.
14. Alex Martin
Company: Abcuro
Title: Chief Executive Officer
Alex Martin is the Chief Executive Officer of Abcuro, a late-stage clinical biotechnology company developing first-in-class immunotherapies for the treatment of autoimmune diseases and cancer through precise modulation of highly cytotoxic T cells. Abcuro’s first-in-class anti- KLRG1 antibody, ulviprubart, being studied in a registrational Phase 2/3 clinical trial, has the potential to stabilize the immune system, halting disease progression. The company’s focus begins with inclusion body myositis (IBM), a rare muscle disease with no current treatments but Abcuro believes this approach can be applied to other autoimmune diseases characterized by cytotoxic T cells as well as cancer.
Coming on board in 2022, Alex along with Chief Medical Officer Jeff Wilkins, revamped the company’s clinical roadmap initiating both a Phase 2/3 study of ulviprubart in patients living with IBM and a 1/2 study of ulviprubart in patients living with T Cell Large Granular Lymphocytic Leukemia (T-LGLL.) Under Alex’s leadership, Abcuro raised $155 million in a Series B financing in 2023, bringing the company to around $245 million raised overall.
Alex brings over 30 years of experience building companies and closing transactions in the biopharmaceutical industry. Most recently he served as CEO of Palladio Biosciences, a clinical stage biopharmaceutical company which was acquired by Centessa Pharmaceuticals. He also previously served as CEO of Realm Therapeutics, acquired by ESSA Pharma.
Alex was also Chief Operating Officer of Intercept Pharmaceuticals, and Chief Finance Officer of BioXell, acquired by Cosmo Pharmaceuticals. He began his career at SmithKline Beecham Pharmaceuticals, where he held roles of increasing responsibility in marketing and business development and later joined Novartis as Vice President of Global Business Development and Licensing.
Alex is Chairman of the board of VERALOX Therapeutics and a Board Director at ESSA Pharmaceuticals. He is an active coach and mentor to other senior executives and a guest lecturer at Wharton and Columbia Business School on biotech, entrepreneurship, and raising capital. He holds a bachelor’s degree from Cornell University and an MBA from Harvard Business School.
15. Liran Belenzon
Company: BenchSci
Title: Chief Executive Officer and Co-Founder
Liran Belenzon is the Co-Founder and Chief Executive Officer of BenchSci, a platform focused on improving drug discovery through artificial intelligence. Founded in 2015, BenchSci’s ASCEND platform aims to address the challenges of productivity in the pharmaceutical industry. The company has rapidly expanded from its original four co-founders to a team of over 350 employees, raising more than $200 million from prominent investors. BenchSci collaborates with 16 of the world’s top 20 pharmaceutical companies, over 4,500 academic institutions, and more than 50,000 scientists.
Before founding BenchSci, Belenzon achieved his commerce and law degrees and sold his first startup. He then immigrated to Canada to pursue an MBA at the Rotman School of Management at the University of Toronto. During his time at Rotman, he participated in the Creative Destruction Lab, where he connected with three fellow PhD students who shared his vision for leveraging AI to enhance drug discovery. As CEO, Belenzon is dedicated to making a positive impact on the world through the advancement of life-saving research.
16. Kevin McRaith
Company: Welldoc
Title: President and Chief Executive Officer
Kevin McRaith is the President and Chief Executive Officer at Welldoc, where he leads the development and commercialization of the company’s AI-driven digital health solution for people living with cardiometabolic conditions. The platform provides personalized, real-time multi-condition coaching across diabetes, hypertension, heart failure, weight management, and prediabetes.
A seasoned digital health innovator and strategic leader with a proven track record of driving transformative change within healthcare, McRaith has played a key role in Welldoc’s growth and development. He has helped guide the company in identifying emerging opportunities, contributing to its diverse business model across the digital health industry. Welldoc provides scalable solutions that support various healthcare organizations, including health plans, health systems, life sciences, and employers. The company works with a growing customer base that includes global companies integrating Welldoc's digital health solutions into their care models and product offerings.
Prior to joining Welldoc, McRaith held senior executive roles at Human Genome Sciences, Genentech and Abbott after starting his career at Baxter Healthcare. He has over 25 years of experience in the life sciences sector including biotech, pharmaceuticals, hospital supplies, and digital health.
17. Lee Ann Fachko
Company: Burlington Medical
Title: Chief Executive Officer
Lee Ann Fachko is the President and Chief Executive Officer of Burlington Medical, a global leader in the radiation protection industry focused on innovation and providing solutions to medical professionals exposed to ionizing radiation while working within the healthcare setting.
The company delivers products manufactured in the U.S. that provide both safety and comfort with a focus on sustainability. Fachko has steered the company’s strategic growth through the acquisition of key competitors, implementing vertical integration initiatives to take control of supply chain and production processes, and continued investments in automation and delivering technology and data solutions that elevate commercial performance, enhance the customer experience, and expand customer reach.
Fachko joined Burlington Medical as the Senior Vice President of Global Sales and Marketing. She was later promoted to Chief Operating Officer in charge of Burlington’s global manufacturing teams. Since her appointment to President and CEO, Fachko has made a significant impact in strengthening the company’s position as a global leader in offering a wide range of radiation protection garments for medical providers in Cardiac Cath labs, radiology, interventional radiology, surgery, and other high-exposure environments.
Fachko has worked with the leadership team to focus the company’s business strategy around four key strategic initiatives: people first, one company, innovation, and financial responsibility. Under these initiatives, the team has focused efforts that drive growth through creating a people centric culture encouraging empowerment and accountability, advancing data analytics and system integration, and investing in R&D efforts that support eco-friendly radiation protective solutions.
Prior to Burlington, Fachko spent 10 years as National Sales Director of Beekley Medical Corporation. Before that, she was the Director of Customer Service for Life Technologies, where she led the global life science company’s customer service team. Fachko holds a bachelor’s degree in accounting from the State University of New York at Fredonia.
18. Matthew Hill
Company: Elegen
Title: Founder and Chief Executive Officer
Matt Hill, PhD, is the Founder and Chief Executive Officer of Elegen, a privately-held company based in the San Francisco Bay Area, focused on accelerating genetic medicine and synthetic biology workflows through innovative cell-free DNA manufacturing technology.
Hill’s career began at Monsanto and progressed through leadership positions, culminating in his role as VP of R&D at Natera, where he co-invented the company’s core technology, contributed to its successful IPO in 2015, and led the commercialization of several prenatal diagnostic products and liquid biopsy oncology tests. With over 13 peer-reviewed scientific publications and nearly two dozen patents and applications, Hill brings extensive experience in innovation across the healthcare continuum.
Frustrated by delays in obtaining custom DNA for discovery workflows, Hill founded Elegen in 2017 with a vision to eliminate DNA bottlenecks. Combining commercial experience and scientific expertise, he innovated every step of the DNA-building process to manufacture long, high-accuracy, complex DNA more quickly.
Under Hill’s leadership, Elegen completed a Series A financing round in 2021 to scale its disruptive technology. In 2023, the company launched ENFINIA DNA, offering industry-leading length, NGS-verified accuracy, and speed to accelerate discovery workflows in the biopharma, agbio, and synbio industries.
In 2024, Elegen raised a $35 million Series B funding round and released a product enhancement for manufacturing high-complexity DNA, including sequences previously rejected by other providers. In addition, Elegen secured a $35 million collaboration with GSK to support the development of mRNA-based vaccines and genetic medicines.
19. Lennie Sliwinski
Company: Trusted Health
Title: Chief Executive Officer
Lennie Sliwinski is Co-Founder and Chief Executive Officer of Trusted Health, where he leverages his extensive background in technology and healthcare to drive innovation and enhance workforce management solutions.
Prior to joining Trusted Health, Sliwinski was the second member of the performance marketing and analytics team at Hired, a curated marketplace connecting job seekers with top companies. There, he developed and managed a multi-channel candidate acquisition program, overseeing a $30 million budget across 17 markets and acquiring over 15,000 new job seekers weekly across North America, EMEA, and APAC.
Sliwinski holds a bachelor’s degree in business administration from Bowling Green State University, a JD from Cornell Law School, and is a licensed attorney in the state of New York.
20. Jordan Feldman
Company: Rightway
Chief Executive Officer and Co-Founder
Jordan Feldman is the Co-Founder and Chief Executive Officer of Rightway, a company he founded to address key challenges in the medical and pharmacy sectors. Growing up with a physician father, Jordan witnessed how having a dedicated, expert advocate could simplify healthcare, improve quality, and reduce costs. At Rightway, his mission is to provide every member with the same level of support by combining clinician-led assistance with a modern app that guides consumers toward the highest-quality and most cost-efficient healthcare options.
Prior to Rightway, Jordan was part of both the Mortgage Trading and Investment Banking teams at Goldman Sachs which he left to help found Redbird Capital Partners, a private equity firm focused on tech-enabled services, healthcare, and communications infrastructure. Jordan holds a bachelor’s degree in government and economics from Harvard University.
21. Derek Lo
Company: Medallion
Title: Chief Executive Officer and Founder
Derek Lo is the Chief Executive Officer and Founder of Medallion, a leading provider network management platform that unites provider operations and empowers end-to-end automation workflows for credentialing, enrollment, and monitoring. Medallion’s mission is to free healthcare teams to focus on what matters by enabling healthcare organizations to quickly and accurately manage and grow their provider networks with AI-powered automation technology.
Since its inception in 2020, Derek has led the company’s growth to over 300 customers, built a team of over 150 employees, and raised $85 million from Sequoia Capital, Spark Capital, Optum Ventures, and many others. He is a second-time founder, whose first company, Py, was acquired by Hired.com in 2019. Derek holds a bachelor’s degree in computer science and statistics from Yale University.
22. Hal Wolf
Company: HIMSS
Title: President and Chief Executive Officer
Harold (Hal) Wolf is the President and Chief Executive Officer of the Healthcare Information and Management Systems Society (HIMSS), a global advisor and thought leader committed to reforming the global health ecosystem through the power of information and technology. A healthcare and informatics leader, Hal has expertise in mHealth, product development, integrated care models, information and technology, and large-scale innovation implementation.
Under Hal’s leadership, the HIMSS professional society has grown to more than 120,000 global members, who are health professionals ranging from nurses to AI researchers. HIMSS provides digital health tools that assess, benchmark, and advise the world’s top health systems, including over 430 major provider organizations, on improving their digital maturity to benefit staff and patients. HIMSS also works with over 500 non-profit health partners and 550 health services organizations to advocate for health equity and improved access to care.
Before joining HIMSS, Wolf served at The Chartis Group as Director and Practice Leader of Information and Digital Health Strategy. Before The Chartis Group, he served as Senior Vice President and COO of Kaiser Permanente’s The Permanente Federation, representing more than 16,000 physicians. Wolf also held executive positions at MTV Networks and Time Warner, and served as senior advisor to McKinsey & Company.
23. Andrew Halasz
Company: Vizzia Technologies
Title: Founder and Chief Executive Officer
Andrew Halasz is the Founder and Chief Executive Officer of Vizza Technologies, a company he founded in 2005. Under his leadership, Vizzia scaled its real-time location systems platform to serve several major hospitals and health systems in the United States. In 2024, Vizzia was acquired by HID Corporation, a subsidiary of the $13 billion Assa Abloy Group.
Andy is a seasoned business leader with over 30 years of experience in various functional and leadership roles across industries for both public and private companies. He was Senior Vice President and Chief Information Officer at Recall Corporation, a global document management company acquired by Iron Mountain. Prior to that, Mr. Halasz developed his business expertise at General Electric, where he held multiple leadership roles, including Vice President of Sales and Marketing.
Andy holds a bachelor’s degree in mechanical engineering from the University of New Mexico and completed the Advanced Management Program at the Harvard Business School.
24. Ty Wang
Company: Angle Health
Title: Chief Executive Officer and Co-Founder
Ty Wang is the Co-Founder and Chief Executive Officer of Angle Health, an AI-enabled, member- and patient-centric healthcare company democratizing access to modern healthcare services through its custom, full-service health plans for employers.
Ty and his co-founder, Anirban Gangopadhyay, both grew up in immigrant families, where access to healthcare and healthcare literacy were significant challenges. They founded Angle Health to address these issues, focusing on providing transparency and simplicity in the healthcare system. Today, Angle Health partners with thousands of brokers and employers across the U.S., primarily serving small- and medium-sized businesses to offer affordable, high-quality healthcare coverage to tens of thousands of Americans.
Prior to founding Angle Health, Ty led major deployments at Palantir Technologies and spent several years in public service with the U.S. government across various foreign and domestic posts. He graduated from Washington University in St. Louis with degrees in electrical engineering and systems engineering. Ty has been published in various academic journals, including Technology in Cancer Research & Treatment and The Journal of Nuclear Medicine.
25. Shankar Musunuri
Company: Ocugen
Title: Chairman, Chief Executive Officer and Co-Founder
Dr. Shankar Musunuri, PhD, MBA, is the Chairman, CEO, and Co-Founder of Ocugen, a publicly traded biotechnology company focused on gene and cell therapies and vaccines. Under his leadership, Ocugen has developed a modifier gene therapy platform for treating blindness diseases, both rare and widespread. The company also works on technologies in orthopedics through a regenerative cell therapy platform and in infectious diseases with an inhalation vaccine platform targeting COVID-19, flu, and a combination vaccine for both.
Dr. Musunuri is a biotech professional with over 30 years of experience in advancing and commercializing a range of products. Before co-founding Ocugen, he held leadership positions at several companies, including large multinational biotechnology firms like Wyeth and Pfizer, as well as start-up biotech companies. During his 15 years at Pfizer, he gained extensive experience in product launches and life-cycle management, including leading the Global Operations Team for Prevnar 13, the world’s top-selling vaccine. Dr. Musunuri also founded Nuron Biotech, which became a commercial company within three years.
Dr. Musunuri holds a PhD in pharmaceutical sciences from the University of Connecticut and an MBA from Duke University, where he now serves on the University’s Innovation and Entrepreneurship Board of Advisors. He is also a Board Member of the Musunuri Family Foundation, a non-profit that provides college scholarships for high school students.
26. Rob Cohen
Company: Livara Health
Title: Chief Executive Officer
Rob Cohen is the Chief Executive Officer of Livara Health, a value-based musculoskeletal management company providing care planning, care navigation and care delivery to improve outcomes and lower costs for people with MSK conditions. Livara partners with commercial and Medicare health plans and providers through flexible value-based payment arrangements, including assuming total cost of MSK care.
Prior to joining Livara, Rob was CEO at Bamboo Health, where he led the company's national expansion from 25 states to 45 states and was responsible for rapid revenue growth in new product lines and new market segments. Prior to Bamboo, Rob served as Market President at Evolent Health, where he was responsible for market growth and managed the P&L and operations for partnerships with health systems.
27. Dave Wessinger
Company: PointClickCare
Title: Chief Executive Officer and Co-Founder
Dave Wessinger is the Co-Founder and Chief Executive Officer of PointClickCare. For more than 20 years, Dave has worked to transform the senior care technology industry and tackle complex challenges across the healthcare continuum.
In 2000, Dave co-founded PointClickCare with his brother Mike, helping to advance healthcare’s digital transformation and improve outcomes for seniors and care teams through technology. Today, PointClickCare boasts one of Canada’s most admired corporate cultures and employs over 2,000 employees who currently serve over 27,000 care providers, establishing PointClickCare as the largest cloud-based healthcare platform in North America.
28. Nicolas Vanden Abeele
Company: Ascom
Title: Chief Executive Officer
Nicolas Vanden Abeele is the Chief Executive Officer of Ascom, a global provider of communication and collaboration solutions for the acute care, long-term care, and enterprise sectors. Its offerings are built on intelligent integrations with software and hardware that leverage open-source technology and are compatible with third-party solutions. Ascom is headquartered in Baar, Switzerland, has operating businesses in 19 countries, and employs around 1,400 people worldwide.
Vanden Abeele is an executive leader with over two decades of technology and industrial expertise. For the past four years, he served as a member of the executive committee and division head of Barco, a global technology company providing visualization solutions for medical and enterprise as well as entertainment applications.
Prior to Barco, Vanden Abeele spent six years as division head and member of the management board of Etex Group and 13 years at Nokia/Alcatel-Lucent in various leadership positions with postings also in the Americas and Asia. He graduated from the Catholic University of Leuven with an MBA and from the College of Europe in Bruges with a master’s degree in international business and European economics.
29. Rony Thomas
Company: LifeNet Health
Title: President and Chief Executive Officer
Rony Thomas has served as President and Chief Executive Officer of LifeNet Health since 2004, leading the organization in the field of regenerative medicine and life sciences. With 1,500 employees globally, LifeNet Health provides organ transplantation, allograft tissue implants, and cell-based research services to hospitals and patients in over 40 countries.
Under Thomas's leadership, LifeNet Health has made significant strides in regenerative medicine and life sciences, securing over 80 U.S. patents and 42 international patents. He has steered the organization to recognize industry trends and focus on growth areas.
In recent years, LifeNet Health has expanded its wound care portfolio through acquisition, entered new global markets, developed advanced allograft technologies, and provided cellular solutions to support drug discovery and safety testing. These efforts have contributed to the distribution of over eleven million grafts, maintaining a strong record of safety and setting new industry standards.
Prior to LifeNet Health, Thomas served as CEO and held other executive leadership positions at USA Instruments, a General Electric company, where he honed his expertise in leading organizations through transformative growth. He holds an MBA from Case Western Reserve University and a master’s degree in engineering and bioengineering from the University of Akron.
30. Rusty Frantz
Company: Nextech Systems
Title: Chief Executive Officer
Rusty Frantz is the Chief Executive Officer of Nextech Systems, a healthcare technology provider focused on serving specialty providers. Since its founding in 1997, Nextech has been committed to delivering solutions and services that improve efficiency, support growth, and enhance patient care.
Frantz joined Nextech after a successful career in healthcare technology. He previously served as President and Chief Executive Officer of NextGen Healthcare, where he was responsible for transforming the company into an integrated provider of ambulatory-focused technology solutions.
Prior to that, Frantz served as Senior Vice President and General Manager at CareFusion, where he led an innovative medication management strategy that significantly expanded and inflected the company’s U.S. and global solutions business. Frantz graduated from Stanford University with a master’s degree in mechanical engineering and from Maine Maritime Academy with an undergraduate degree in marine engineering.
31. Stefan Fritsch
Company: Grünhorn
Title: Chief Executive Officer
Stefan Fritsch is the Chief Executive Officer of Grünhorn, a medical cannabis company he founded in 2020, four years before Germany legalized cannabis for recreational use. Fritsch’s goal was to build a European cannabis company that could compete with established North American players.
Grünhorn eventually became one of the largest online cannabis pharmacies in Germany, handling about 25% of all cannabis prescriptions before the country's legalization in April 2024. The company is also the only cannabis pharmacy in Germany with an in-house research lab, where it has analyzed over 250 cannabis strains to help refine strain categorization.
This research has contributed to tools like Grünhorn’s proprietary "digital flower-finder," which assists doctors and patients in selecting cannabis strains based on terpene profiles. Additionally, Fritsch launched the Grünhorn Academy to provide education on medical cannabis to patients and healthcare professionals.
Today, Grünhorn operates as Germany’s largest cannabis group, with an online pharmacy, its own wholesaler, and a range of Grünhorn-branded products distributed across Europe. The company is planning to expand internationally, with product launches in Poland, the UK, and Australia.
32. Anton Derlyatka
Company: Sweatcoin
Title: Chief Executive Officer and Co-Founder
Anton Derlyatka is the Co-Founder and Chief Executive Officer of Sweatcoin, one of the largest health and fitness apps globally with over 170 million registered users. Sweatcoin’s step-tracking app motivates users to increase their activity by offering rewards and gamification. The app is also a partner with the UK's National Health Service (NHS) for the Diabetes Prevention Program. Anton is focused on promoting preventative health and addressing the issue of inactivity, which contributes to many chronic health conditions worldwide.
Derlyatka is an experienced executive with a focus on building high-growth, high-velocity B2C businesses powered by product virality and network effects. He has over 20 years of experience as an entrepreneur, investor, and manager, starting his career in marketing at Pepsi-Cola and Reebok, before developing a sports management consulting practice with A.T. Kearney in London.
Anton has also worked in the talent technology and recruitment sectors. In 2011, he founded Talent Equity Ventures, the first seed fund focusing on talent and HR technology, and later co-founded TalentTechLabs, an early-stage incubator in the talent and HR tech space.
As an angel investor, Anton focuses on fitness, sports and health technology in the U.S. and UK. Anton graduated from London Business School and furthered his education at Sanford and UC Berkeley. He also holds a master’s degree in applied math from MEPhI.
33. Georg Harnoncourt
Company: ndd Medical Technologies
Title: Chief Executive Officer
Georg Harnoncourt is the Chief Executive Officer of ndd Medical Technologies. He first joined the company in 1995 as Assistant Manager. For more than 20 years, ndd has focused on improving the early detection and accurate diagnosis of chronic lung diseases, such as COPD, through its EasyOne products. Under Harnoncourt’s leadership, ndd has expanded its global reach, making its innovative pulmonary function testing (PFT) devices available in over 100 countries and supporting research and awareness efforts in the field.
34. Jeff Fallon
Company: eVideon
Title: Chairman and Chief Executive Officer
Jeff Fallon is the Chairman and Chief Executive Officer of eVideon, a provider of smart hospital room solutions. He has led the company in advancing healthcare delivery through technology, focusing on improving the experience for patients, families, clinicians, and hospital staff. Under his leadership, eVideon’s Vibe Health platform has been adopted by top hospitals and health systems across the country to create more efficient and patient-centered care environments.
Jeff’s focus on leveraging technology to address healthcare challenges has guided the strategic direction of eVideon. His leadership has contributed to the company’s growth and its position in the market. Jeff’s commitment to healthcare innovation and collaboration has been key in driving the company toward its goals, creating an environment that supports both employees and business partners.
35. Eric Shaff
Company: Seres Therapeutics Biotech
Title: President and Chief Executive Officer
Eric Shaff is the President and Chief Executive Officer of Seres Therapeutics, a clinical-stage company focused on improving patient outcomes in medically vulnerable populations through novel live biotherapeutics. Shaff previously served as the Executive Vice President and Chief Operating and Financial Officer at Seres, bringing over 20 years of experience in biotechnology finance, corporate development, and capital markets.
Prior to joining Seres, Shaff served as Vice President of Corporate Finance at Momenta Pharmaceuticals, where he helped manage Momenta’s accounting, finance, planning, and procurement functions, as well as contributing to Momenta’s investor relations efforts.
Prior to joining Momenta, Shaff was Vice President of Finance in Genzyme’s Rare Genetic Disease Division, responsible for a global portfolio of products. Shaff held several positions at Genzyme in business unit finance, corporate finance, and corporate development. Prior to Genzyme, Shaff worked in corporate finance at Pfizer and worked in investment banking for Broadview International (now Jefferies).
Shaff also serves on the board of directors of Sigilon Therapeutics. He holds a bachelor’s degree in political science and economics from the University of Pennsylvania and an MBA in finance from the Johnson Graduate School of Management at Cornell University.
36. Kevin Ali
Company: Organon
Title: Chief Executive Officer
Kevin Ali is the Chief Executive Officer and board member of Organon, a global healthcare company with the vision of creating a better and healthier every day for women around the world. Ali led the formation of Organon in 2021 to address the significant health issues that women face and deliver impactful solutions all over the world.
Ali has more than three decades of healthcare and commercial experience from Merck, where he has held a number of leadership roles. Before leading Organon, Ali was president of Merck’s international business, responsible for all commercial markets outside the U.S. which account for 96% of the world's population and over half of Merck’s pharmaceutical revenues.
Under Ali’s leadership, the international business was a significant driver of Merck’s growth. Previously, Ali served as President of the emerging markets region, where he transformed the performance of many countries for sustained growth and strength. Earlier in his career, Ali was the Managing Director of Germany and Turkey and also led key therapeutic franchises for the company. Ali holds an MBA from Santa Clara University and a bachelor’s degree from the University of California, Berkeley.
37. Frank Laukien
Company: Bruker
Title: Chairman, President and Chief Executive Officer
Dr. Frank H. Laukien has served as Chairman, President, and Chief Executive Officer of Bruker since 1991. Bruker develops high-performance scientific instruments and analytical solutions that support breakthroughs in post-genomic discoveries and new applications in various fields. The company’s technologies enable scientists to study life and materials at molecular, cellular, and microscopic levels.
Laukien also serves as a director for various Bruker subsidiaries. Previously, he served as a Director of ALDA, including a term as Chairman from 2002 to 2003. Dr. Laukien holds a bachelor’s degree in physics from MIT and a PhD in chemical physics from Harvard University.
38. Fred Lampropoulos
Company: Merit Medical Systems
Title: Chief Executive Officer and President
Fred Lampropoulos is the President and Chief Executive Officer of Merit Medical Systems, which he founded in 1987 after serving as Chairman and Chief Executive of Utah Medical. Merit Medical Systems develops, manufactures, and distributes proprietary medical devices used in interventional, diagnostic, and therapeutic procedures, particularly in cardiology, radiology, oncology, critical care, and endoscopy. The company serves customers worldwide, with a domestic and international sales force and clinical support team of over 700 individuals, and employs approximately 7,200 people globally.
Lampropoulos has invented and holds more than 200 patents on devices used in the diagnostic and therapeutic treatment of cardiac, peripheral, gastrointestinal, and pulmonary conditions. He is a former Special Forces Officer and an Honorary Colonel in the Utah National Guard. He holds several honorary doctorates, including doctorate in business administration from Westminster College in Salt Lake City, recognizing his contribution to and development of industry and education within the state of Utah.
39. William Feehery
Company: Certara
Title: Chief Executive Officer
Dr. William Feehery is the Chief Executive Officer of Certara, a company that uses biosimulation software, technology, and services to enhance drug discovery and development. Certara’s clients include over 2,400 biopharmaceutical companies, academic institutions, and regulatory agencies across 66 countries.
Dr. Feehery joins Certara from DuPont, where he was President of DuPont Industrial Biosciences. He joined DuPont in 2002 and held various management roles in high-growth businesses. Dr. Feehery also has experience in venture capital and as a consultant for the Boston Consulting Group. He also serves on the board of West Pharmaceutical Services. Dr. Feehery holds a Ph.D. in chemical engineering and an MBA from MIT, as well as a bachelor’s degree in chemical engineering from the University of Pennsylvania.
40. Nitin Sahney
Company: PharmaCord
Title: Founder and Chief Executive Officer
Nitin Sahney is the Founder and Chief Executive Officer of PharmaCord, a company focused on improving the patient experience. Since its founding, Sahney has guided PharmaCord through significant growth, expanding the workforce to over 1,300 employees in just seven years within the patient services industry.
Previously, Sahney served as President and CEO at Omnicare. Before that he founded and served as CEO at RxCrossroads. Earlier in his career he worked with Cardinal Health as a general manager in nexus healthcare and corporate development. Sahney earned an MBA from Clarion University and an undergraduate degree in economics from Punjab University.
41. Paul Evans
Company: Velocity Clinical Research
Title: President and Chief Executive Officer
Paul Evans joined Velocity Clinical Research as President and Chief Executive Officer in 2018, bringing 26 years of experience in the site business, with 13 years spent running clinical sites and another 13 years managing them from the Sponsor/CRO side. Velocity Clinical Research is a leading organization of fully integrated clinical research sites. With over 90 sites and 220 investigators, the company collaborates with pharmaceutical and biotechnology companies to research new drugs, medical devices, diagnostics, and combination products aimed at improving human health.
Evans previously held roles as Corporate VP, Global Site Solutions at Parexel, VP, Global Site Management at IQVIA, and Founder and Managing Director of Synexus. He holds a PhD in biomedical engineering from the University of London. Evans has been a member of the Association of Clinical Research Professionals (ACRP) Board of Trustees since 2017 and chaired the committee in 2020.
42. Vafa Jamali
Company: ZimVie
Title: President and Chief Executive Officer
Vafa Jamali is the President and Chief Executive Officer of ZimVie. With more than 25 years of experience in the medical device industry, Jamali was recruited in 2021 to join Zimmer Biomet's Executive Committee and lead the independent organization. ZimVie is a global leader in the dental market, developing, manufacturing, and delivering a comprehensive portfolio of products and solutions for dental tooth replacement and restoration procedures.
Prior to his appointment at ZimVie, Jamali was Senior Vice President and President of the Respiratory, Gastrointestinal, and Informatics (RGI) division at Medtronic. He also served as Senior Vice President and President of Early Technologies at Medtronic and Vice President and General Manager of GI Solutions. Before joining Medtronic, Jamali held leadership roles at Covidien, Cardinal Health, and Baxter International.
Jamali holds a bachelor of commerce degree from the University of Alberta in Edmonton, Canada, and has completed a number of executive leadership programs, including the Harvard Executive Leadership Program in 2020.
43. Mark Foley
Company: Revance
Title: Chief Executive Officer
Mark J. Foley is the Chief Executive Officer of Revance Therapeutics and has served as a member of the Company’s board of directors since September 2017. Revance is a biotechnology company focused on developing aesthetic and therapeutic solutions aimed at improving patient outcomes and physician experiences. Its portfolio includes DAXXIFY (DaxibotulinumtoxinA-lanm) for injection and the RHA Collection of dermal fillers.
Previously, Foley was Chairman, President, and CEO of ZELTIQ Aesthetics. Foley also served as a Managing Director of RWI Ventures, a venture capital firm focused on life sciences, networking, semiconductor, and software investments. Foley has over 25 years of experience in the healthcare field, having served in a variety of senior operating roles in both large public companies and venture-backed startups, including U.S. Surgical Corporation, Guidant Corporation, Devices for Vascular Intervention, Perclose, and Ventrica.
Foley holds a bachelor’s degree from the University of Notre Dame and is a named inventor on 17 patent applications.
44. Jagath Wanninayake
Company: Suvoda
Title: Co-Founder, Chairman and Chief Executive Officer
Jagath Wanninayake is the Co-Founder, Chairman, Chief Executive Officer of Suvoda, a global clinical trial technology company specializing in complex, life-sustaining studies in therapeutic areas like oncology, central nervous system, and rare diseases. Founded in 2013 by experts in eClinical technologies, Suvoda empowers clinical trial professionals to manage the urgent moments in urgent trials through advanced software solutions delivered on a single platform.
Wanninayake is an entrepreneur and experienced executive with a background in founding and leading innovative software companies. He previously served as Co-Founder, Chairman, and CEO of Clarix, where he led the team that developed the first fully web-integrated randomization and trial supply management system with the industry’s shortest deployment timeline.
Subsequently, Wanninayake served as a corporate officer and a member of the operating committee at Phase Forward. He also co-founded Jamity Records, an independent record label which produced several albums, and co-founded Mixette, a digital gifting startup. He holds a bachelor’s degree in economics with a concentration in public policy from Swarthmore College.
45. Patrick Miles
Company: Alphatec Spine
Title: Chairman and Chief Executive Officer
Patrick S. Miles has served as Chairman and Chief Executive Officer of Alphatec Holdings and Alphatec Spine since 2017. ATEC is a medical device company focused on advancing spine surgery through innovation. The company concentrates its efforts on improving spine surgery by redesigning and integrating the technologies required for better clinical outcomes.
Miles has over 20 years of experience in the orthopedic industry. Before joining Alphatec Holdings, he was Vice Chairman of NuVasive, where he contributed to the company’s strategic plans for spine surgery and technology development. Miles previously held several leadership roles at NuVasive, including President and Chief Operating Officer, President of Global Products and Services, and Senior Vice President of Marketing. He also served as Director of Marketing at ORATEC Interventions and held various positions at Medtronic Sofamor Danek and Smith & Nephew. Miles holds a bachelor’s degree in finance from Mercer University.
46. Tom Sellig
Company: Adare Pharma Solutions
Title: Chief Executive Officer
Tom Sellig is the Chief Executive Officer of Adare Pharma Solutions. He brings more than 30 years of global experience in the life sciences industry, including experience scaling organizations and driving growth in the CDMO and pharma services space. Sellig previously served as Chief Executive Officer of LabConnect, a clinical trial laboratory services organization. Under his leadership, the company more than doubled in revenue and underwent significant team expansion to meet the growing needs of the biopharma industry.
Prior to LabConnect, Sellig was Chief Commercial Officer at ConnectiveRx, where he was responsible for all commercial and customer-facing activity at the patient support and patient access company. Before that, Sellig was Senior Vice President of Global Sales at Patheon, where he played an integral role in the company’s sale to and integration with Thermo Fisher. Previously, he served as the Global Vice President of Sales and Client Services at Covance. Sellig holds a bachelor’s degree in economics from Vanderbilt University and an MBA from New York University.
47. Todd Gustin
Company: Genoa Healthcare
Title: Chief Executive Officer
Todd Gustin is the Chief Executive Officer of Genoa Healthcare. Dedicated to serving the needs of those in the behavioral health and substance use disorder communities, and others who have complex, chronic health conditions, Genoa Healthcare is the largest provider of behavioral health pharmacy and clinical services for individuals with behavioral health and other complex, chronic health conditions in the U.S.
Gustin brings 25 years of experience to his current role. Before joining Genoa Healthcare, he served as SVP of Inorganic Growth and Transformation at OptumInsight. Before that he was President of the Technology Solutions Division at Optum360. Earlier in his career he worked with RBC Capital Markets in investment banking. Gustin graduated from the University of Minnesota in Carlson School of Management with an MBA in finance and from Colorado College with an undergraduate degree in economics.
48. Barry Greene
Company: Sage Therapeutics
Title: President and Chief Executive Officer
Barry Greene is the Chief Executive Officer and a member of the Board of Directors at Sage Therapeutics, a biopharmaceutical company focused on developing brain health medicines. Sage has developed the only two FDA-approved treatments for postpartum depression and is advancing a pipeline to address unmet needs in brain health. Greene joined Sage in 2020, bringing more than 30 years of experience in the biopharmaceutical industry. Prior to joining Sage, he served as President of Alnylam Pharmaceuticals since 2007, and previously held the role of Chief Operating Officer after joining the company in 2003.
Prior to his tenure at Alnylam, Greene was the General Manager of Oncology at Millennium Pharmaceuticals, where he led global strategy and execution for its oncology business, culminating in the successful U.S. Food and Drug Administration approval and launch of VELCADE (bortezomib) in mid-2003.
Prior to joining Millennium, Greene served as Executive Vice President and Chief Business Officer for Mediconsult.com, a healthcare consulting company. Earlier in Greene’s career, he held multiple leadership positions at AstraZeneca, and was a Partner at Andersen Consulting, where he was responsible for the pharmaceutical and biotechnology marketing and sales practice. Greene holds a bachelor’s degree in industrial engineering from the University of Pittsburgh.
49. Murali Aravamudan
Company: Nference
Title: Co-Founder and Chief Executive Officer
Murali Aravamudan is the Co-Founder and Chief Executive Officer of Nference, a life sciences startup focused on transforming healthcare by making biomedical knowledge computable through its artificial intelligence software platform. A serial entrepreneur, inventor, and engineer, Aravamudan has built successful technology companies in the media and telecom sectors. In addition to leading Nference, he serves as the CEO of its affiliate ventures Pramana and Vimana, and as Executive Chairman of the Board at Anumana.
Previously, Aravamudan co-founded Veveo, a company focused on enabling efficient content discovery on input-constrained devices like televisions and mobile phones. Before that, he was Vice President and General Manager of the Winphoria Division at Motorola, following the acquisition of Winphoria Networks, a company he founded in 2000 and led as CTO until its acquisition. Aravamudan helped raise $54 million in equity for Winphoria, which was acquired by Motorola for approximately $200 million. Earlier in his career, he served as Vice President and Chief Technology Officer of the Communications Software Business at Lucent Technologies.
Aravamudan holds a master’s degree in electrical communication engineering from the Indian Institute of Science, Bengaluru.
50. Brian Webster
Company: Kestra Medical Technologies
Title: President and Chief Executive Officer
Brian Webster is the President and Chief Executive Officer of Kestra Medical Technologies, a privately held wearable medical device and digital healthcare company. With over 32 years of experience in the medical device industry, including 18 years as President and CEO, Webster leads Kestra in providing diagnostic monitoring and therapeutic technologies for cardiac patients. Kestra was founded in 2014 by leaders from the external (AED) and implantable (ICD) defibrillation industries.
Webster previously held executive positions including VP roles in operations, sales, and marketing. He brings broad knowledge of emergency medicine, the cardiac field, and the external defibrillation industry. Webster graduated from Seattle University with an MBA and from the University of Puget Sound with an undergraduate degree in business administration.
